76650 Federal Register / Vol. 65, No. 236 / Thursday, December 7, 2000 / Notices

Numbers: PHS 398, 2590, 2271, 3734

and HHS 568.

Need and Use of Information

Collection: The application is used by

applicants to request Federal assistance

for research and research-related

training. The other related forms are

used for trainee appointment, final

invention reporting, and to relinquish

rights to a research grant.

Frequency of response: Applicants

may submit applications for published

receipt dates. If awarded, annual

progress is reported and trainees may be

appointed or reappointed.

Affected Public: Individuals or

Households; Business or other for-profit;

Not-for-profit institutions; Federal

Government; and State, Local or Tribal

Government.

Type of Respondents: Adult scientific

professionals. The annual reporting

burden is as follows:

Estimated Number of Respondents:

114,407;

Estimated Number of Responses per

Respondent: 1;

Average Burden Hours Per Response:

12.040; and

Estimated Total Annual Burden

Hours Requested: 1,377,548. The

estimated annualized cost to

respondents is $48,214,180.

Request for Comments

Written comments and/or suggestions

from the public and affected agencies

are invited on one or more of the

following points: (1) Whether the

proposed collection of information is

necessary for the proper performance of

the function of the agency, including

whether the information will have

practical utility; (2) The accuracy of the

agency’s estimate of the burden of the

proposed collection of information,

including the validity of the

methodology and assumptions used; (3)

Ways to enhance the quality, utility, and

clarity of the information to be

collected; and (4) Ways to minimize the

burden of the collection of information

on those who are to respond, including

the use of appropriate automated,

electronic, mechanical, or other

technological collection techniques or

other forms of information technology.

FOR FURTHER INFORMATION CONTACT: To

request more information on the

proposed project or to obtain a copy of

the data collection plans and

instruments, contact Ms. Jan Heffernan,

Division of Grants Policy, Office of

Policy for Extramural Research

Administration, NIH, Rockledge 1

Building, Room 1196, 6705 Rockledge

Drive, Bethesda, MD 20892–7974, or

call non-toll-free number (301) 435–

0940, or E-mail your request, including

your address to: Heffernj@OD.NIH.GOV

Comments Due Date

Comments regarding this information

collection are best assured of having

their full effect if received on or before

February 5, 2001.

Dated: November 29, 2000.

Carol Tippery,

Acting Director, OPERA, NIH, GOV.

[FR Doc. 00–31213 Filed 12–6–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Call for

Nominations for the National Cancer

Institute Director’s Liaison Group

The National Cancer Institute (NCI),

the federal government’s primary

agency for cancer research, is seeking

nominations for five new members of

the NCI Director’s Consumer Liaison

Group (DCLG) who will be appointed in

July 2001. The DCLG helps NCI to

identify appropriate advocates to serve

on its program and policy advisory

committees, and it serves as a channel

for consumer advocates to voice their

views and concerns. The DCLG is a

federal chartered advisory committee of

the National Cancer Institute (NCI). It

consists of 15 consumer advocates who

are involved in cancer advocacy and

who reflect the diversity among those

whose lives are affected by cancer.

NCI brings together these advocates

from many communities to advise and

make recommendations to the Director,

NCI from the consumer advocate

perspective on a wide variety of issues,

programs and research priorities. All

DCLG members must be U.S. citizens.

Specifically the DCLG members:

• Help develop and establish

processes, mechanisms, and criteria for

identifying appropriate consumer

advocates to serve on a variety of

program and policy advisory

committees responsible for advancing

the mission of the NCI.

• Serve as a primary forum for

discussing issues and concerns and

exchanging viewpoints that are

important to the broad development of

the NCI programmatic and research

priorities.

• Establish and maintain strong

collaborations between the NCI and the

cancer advocacy community to reach

common goals.

Eligibility Requirements for Individual

Members

To serve on the DCLG, a member must

meet the following minimum eligibility

requirements:

• Be involved in the cancer

experience as a cancer survivor, a

person affected by the suffering and

consequences of cancer, or a

professional or volunteer who works

with survivors or those affected.

• Represent a constituency (formally

or informally) with whom she or he

communicates regularly on cancer

issues and be able to serve as a conduit

for information both to and from his/her

constituency.

DCLG members must be committed to

participating in all activities of the

DCLG which includes at least two

meetings a year in Bethesda.

Criteria for Evaluating Individual

Candidates

Nominees who meet the minimum

eligibility requirements will be further

assessed based on the following criteria:

• Cancer Advocacy experience

• Ability to communicate effectively

• Ability to represent broad issues,

think ‘‘globally’’

• Ability to contribute to an effective

group process

• Leadership ability

Characteristics of the DCLG

In addition to the criteria for

individual candidates, the following

characteristics of the DCLG as a group

are intended to ensure that it reflects the

breadth and diversity of the consumer

advocacy community:

• Multicultural diversity

• A broad mix of cancer sites

• Representation of the medically

underserved

• Men and women

• A range of organizations (local/

regional and national)

• Age diversity

• Geographic diversity (rural/urban

mix)

Selection Process

A call for nominations is

disseminated annually to a broad range

of groups, including local, regional and

national organizations, to encourage

nominations of candidates reflecting the

diversity sought for the DCLG. All

nominees are screened for eligibility,

then evaluated according to the criteria.

A list of highly qualified candidates

who reflect balance and diversity of

representation is forwarded to the

Director, NCI, who selects the DCLG

members. The original members of the

DCLG endorsed this process, which will

be used to select future members.

Federal Register / Vol. 65, No. 236 / Thursday, December 7, 2000 / Notices 76651

NCI encourages nomination of

candidates reflecting the diversity

sought on the DCLG. Nominations can

be made by organizations, including

local/regional and national groups, or

individuals, including self-nominations.

To receive a nomination package for the

DCLG, send your name, advocacy/

voluntary organization affiliation (if

any), address and phone number to the

Office of Liaison Activities, NCI, c/o

Palladian Partners, 1010 Wayne

Avenue, Suite 1200, Silver Spring, MD

20910, FAX (301) 650 8676.

Nominations must be postmarked by

February 15, 2001.

Dated: November 30, 2000.

LaVerne Stringfield,

Director, Office of Federal Advisory

Committee Policy, National Institutes of

Health.

[FR Doc. 00–31197 Filed 12–6–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions;

Availability for Licensing

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The inventions listed below

are owned by agencies of the U.S.

Government and are available for

licensing in the U.S. in accordance with

35 U.S.C. 207 to achieve expeditious

commercialization of results of

federally-funded research and

development. Foreign patent

applications are filed on selected

inventions to extend market coverage

for companies and may also be available

for licensing.

ADDRESSES: Licensing information and

copies of the U.S. patent applications

listed below may be obtained by writing

to the indicated licensing contact at the

Office of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville,

Maryland 20852–3804; telephone: 301/

496–7057; fax: 301/402–0220. A signed

Confidential Disclosure Agreement will

be required to receive copies of the

patent applications.

Immunoglobulin-G Constant Region

Fusion Proteins as Molecular Weight

Markers

Stephen V. Angeloni, Ph.D. (NIDDK)

DHHS Reference No. E–292–00/0,

Licensing Contact: Marlene Shinn;

301/496–7056 ext. 285; e-mail:

shinnm@od.nih.gov

The technology portrayed in this

invention is available through a

Biological Materials License as a

research tool and for use in diagnostic

tests. Current methods of protein

detection and size determination can be

made more efficient by the utilization of

more stable protein markers that cover

a wider range of molecular weights for

western blotting and other diagnostics

applications. As embodied in this

invention, construction of recombinant

proteins containing constant regions of

Immunoglobulin-G from mouse, rabbit

and other species, allow the production

of protein standards that can be detected

simultaneously on the same western

blot as the sample proteins. Such

markers will increase the accuracy in

determining sample protein size and in

combination with recombinant or

chemically labeled second antibodies,

will allow the detection of an increased

number of sample proteins

simultaneously on the same blot.

A Forward Mutational Assay for Use

With PhiX174 Transgenic Mice

Carrie R. Valentine (FDA), Heinrich V.

Malling (NIEHS), Bentley A. Fane

(Univ. of Arizona)

DHHS Reference No. E–254–00/0 filed

11 July, 2000, Licensing Contact:

Marlene Shinn; 301/496–7056 ext.

285; email: ms482m@nih.gov

The aforementioned invention is

currently available through a Biological

Materials License as a research tool.

This assay can detect 19 different base

substitutions at 13 different sites in gene

A of the PhiX174 transgene present in

the transgenic Malling mouse and is an

improvement over the previous

reversion assay, which was limited to

mutation at a single site. The ability to

detect mutations at multiple sites will

allow the detection of mutagenic test

compounds with affinity for different

sequence contexts, while retaining the

advantage of the inexpensive recovery

of this transgene, which is by

electroporation.

The evaluation of new drugs for their

potential for inducing mutations is a

necessary part of evaluating the safety of

pharmaceuticals or environmental

chemicals. One advantage of this assay

is that it may be automated to be

performed in microplate dishes. In

addition, this assay has the potential to

be utilized in a microarray system

because of the limited number of

possible mutations. Therefore, it would

be more rapid and less expensive than

the currently used transgenic systems.

Adult Human Dental Pulp Stem Cells in

vitro and in vivo

Dr. Songtao Shi et al. (NIDCR)

DHHS Reference No. E–233–00/0 filed

21 July 2000, Licensing Contact:

Marlene Shinn; 301/496–7056 ext.

285; e-mail: shinnm@od.nih.gov

Many individuals with ongoing and

severe dental problems are faced with

the prospect of permanent tooth loss.

Examples include dentinal degradation

due to caries or periodontal disease;

(accidental) injury to the mouth; and

surgical removal of teeth due to tumors

associated with the jaw. Clearly, a

technology that offers a possible

alternative to artificial dentures by

designing and transplanting a set of

living teeth fashioned from the patient’s

own pulp cells would greatly improve

the individual’s quality of life.

The NIH announces a new technology

wherein dental pulp stem cells from an

individual’s own postnatal dental pulp

tissue (one or two wisdom teeth) can

potentially be used to engineer healthy

living teeth. This technology is based

upon the discovery of a subpopulation

of cells within normal human dental

pulp tissue that has the ability to grow

and proliferate in vitro. These (dental

pulp) stem cells can be induced under

defined culture conditions to form

calcified nodules in vitro and have been

shown to differentiate into a dentin/

pulp like structure in vivo.

PTH2 and PTH1 Receptor Ligands

Ted B. Usdin and Samuel R. Hoare

(NIMH)

DHHS Reference No. E–123–99/1 filed

15 June 2000, Licensing Contact:

Norbert Pontzer; 301/496–7735, ext.

284; e-mail: pontzern@od.nih.gov

Parathyroid hormone receptors found

on osteoblasts in bone and renal tubule

cells in kidney elevate blood calcium

levels when stimulated by parathyroid

hormone (PTH) and PTH-related protein

(PTHrP). Excessive secretion of PTH

from the parathyroid gland results in

primary hyperparathyroidism.

Production of PTHrP by various tumors

results in humoral hypercalcemia of

malignancy. In both of these conditions,

excessive blood calcium levels lead to

clinically significant morbidity. A

parathyroid hormone antagonist could

therefore have therapeutic value.

Until now, no effective antagonists for

the classical parathyroid hormone

receptor (PTH1 receptor) were known.

This invention describes a peptide

which binds with high affinity

(Kd = 1.3 ± 0.1 nM, dissociation T1/2 = 14

min.) and acts as purely competitive

antagonist at the PTH1 receptor. This

novel peptide is related to